Table of Contents
ISRN Psychiatry
Volume 2012 (2012), Article ID 595141, 5 pages
http://dx.doi.org/10.5402/2012/595141
Research Article

Comparative Evaluation of Forced Swim Test and Tail Suspension Test as Models of Negative Symptom of Schizophrenia in Rodents

Neuropharmacology Unit, Division of Pharmacology, Central Drug Research Institute, CSIR, Uttar Pradesh, Lucknow 226001, India

Received 1 September 2011; Accepted 2 October 2011

Academic Editors: R. P. Rajarethinam and R. Yoshimura

Copyright © 2012 Manavi Chatterjee et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. G. K. Thaker and W. T. Carpenter Jr., “Advances in schizophrenia,” Nature Medicine, vol. 7, no. 6, pp. 667–671, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  2. V. I. Reus, Mental Disorders, McGraw-Hill, New York, NY, USA, 2008.
  3. M. S. Keshavan, V. A. Diwadkar, D. M. Montrose, R. Rajarethinam, and J. A. Sweeney, “Premorbid indicators and risk for schizophrenia: a selective review and update,” Schizophrenia Research, vol. 79, no. 1, pp. 45–57, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  4. K. H. Nuechterlein and M. E. Dawson, “Information processing and attentional functioning in the developmental course of schizophrenic disorders,” Schizophrenia Bulletin, vol. 10, no. 2, pp. 160–203, 1984. View at Google Scholar · View at Scopus
  5. A. Laurent, M. Saoud, T. Bougerol et al., “Attentional deficits in patients with schizophrenia and in their non-psychotic first-degree relatives,” Psychiatry Research, vol. 89, no. 3, pp. 147–159, 1999. View at Publisher · View at Google Scholar · View at Scopus
  6. S. McLaren, J. C. Cookson, and T. Silverstone, “Positive and negative symptoms, depression and social disability in chronic schizophrenia: a comparative trial of bromperidol and fluphenazine decanoates,” International Clinical Psychopharmacology, vol. 7, no. 2, pp. 67–72, 1992. View at Google Scholar · View at Scopus
  7. A. Breier, R. W. Buchanan, B. Kirkpatrick et al., “Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia,” American Journal of Psychiatry, vol. 151, no. 1, pp. 20–26, 1994. View at Google Scholar · View at Scopus
  8. L. Steru, R. Chermat, B. Thierry, and P. Simon, “The tail suspension test: a new method for screening antidepressants in mice,” Psychopharmacology, vol. 85, no. 3, pp. 367–370, 1985. View at Google Scholar · View at Scopus
  9. R. D. Porsolt, A. Bertin, and M. Jalfre, “Behavioral despair in mice: a primary screening test for antidepressants,” Archives Internationales de Pharmacodynamie et de Therapie, vol. 229, no. 2, pp. 327–336, 1977. View at Google Scholar · View at Scopus
  10. Y. Noda, K. Yamada, H. Furukawa, and T. Nabeshima, “Enhancement of immobility in a forced swimming test by subacute or repeated treatment with phencyclidine: a new model of schizophrenia,” British Journal of Pharmacology, vol. 116, no. 5, pp. 2531–2537, 1995. View at Google Scholar · View at Scopus
  11. Y. Noda, T. Mamiya, H. Furukawa, and T. Nabeshima, “Effects of antidepressants on phencyclidine-induced enhancement of immobility in a forced swimming test in mice,” European Journal of Pharmacology, vol. 324, no. 2-3, pp. 135–140, 1997. View at Publisher · View at Google Scholar · View at Scopus
  12. A. Bleich, S. L. Brown, R. Kahn, and H. M. Van Praag, “The role of serotonin in schizophrenia,” Schizophrenia Bulletin, vol. 14, no. 2, pp. 297–315, 1988. View at Google Scholar · View at Scopus
  13. H. Y. Meltzer, “Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia,” Psychopharmacology, vol. 99, pp. S18–S27, 1989. View at Google Scholar · View at Scopus
  14. S. Kapur and G. Remington, “Serotonin-dopamine interaction and its relevance to schizophrenia,” American Journal of Psychiatry, vol. 153, no. 4, pp. 466–476, 1996. View at Google Scholar · View at Scopus
  15. A. J. Gelenberg and J. C. Doller, “Clozapine versus chlorpromazine for the treatment of schizophrenia: preliminary results from a double-blind study,” Journal of Clinical Psychiatry, vol. 40, no. 5, pp. 238–240, 1979. View at Google Scholar · View at Scopus
  16. J. F. Castelao, L. Ferreira, Y. G. Gelders, and S. L. E. Heylen, “The efficacy of the D2 and 5-HT2 antagonist risperidone (R 64 766) in the treatment of chronic psychosis. An open dose-finding study,” Schizophrenia Research, vol. 2, no. 4-5, pp. 411–415, 1989. View at Publisher · View at Google Scholar · View at Scopus
  17. J. A. Lieberman, J. M. Kane, and C. A. Johns, “Clozapine: guidelines for clinical management,” Journal of Clinical Psychiatry, vol. 50, no. 9, pp. 329–338, 1989. View at Google Scholar · View at Scopus
  18. B. Angrist, J. Rotrosen, and S. Gershon, “Differential effects of amphetamine and neuroleptics on negative vs. positive symptoms in schizophrenia,” Psychopharmacology, vol. 72, pp. 17–19, 1980. View at Google Scholar